Tencent Invests in Neowise Bio, a Pioneer in Solid Tumor TCR-T Cell Therapy

Source: Securities Times

People's Finance News, February 2nd: According to Qichacha APP, recently, Neowise Biotechnology (Suzhou) Co., Ltd. underwent a business registration change, adding Guangxi Tencent Venture Investment Co., Ltd. as shareholders, while the registered capital increased to 7.7922 million yuan. Qichacha information shows that the company was established in 2020, with a business scope including pharmaceutical production; technical services, technical development, technical consultation, technical exchange, technical transfer, and technical promotion; and medical research and experimental development. According to its official website, the company is an innovative enterprise focused on developing TCR-T immunotherapy drugs for solid tumors, as well as researching clinical technologies and their transformation.